Apremilast as anti-pruritic treatment in patients with prurigo nodularis

Registry ID

EUCTR2016-003018-29

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Herlev and Gentofte Hospital

Start date

2017-05-31

Completion date

2019-02-27

Last update

2026-08-16

Conditions

• Prurigo nodularis

Summary

This study will evaluate the anti-pruritic effect of apremilast in patients with known PN. 1. Reduction in mean absolute VAS-pruritus score after 12 weeks treatment with apremilast compared to mean VAS-pruritus score before treatment with apremilast

Locations

• , , Denmark

Related clinical trials

• SWITCH project: Definition of treat-to-target criteria for shared decision making between patients and physicians about initiating, continuing or switching systemic treatment for chronic prurigo and chronic pruritus
• Use of the WHO-5 in chronic pruritus and chronic prurigo and development of a skin well-being questionnaire
• Definition of Severity and Descriptors of Chronic Prurigo – Harmonization of European Prurigo Documentation
• Acceptance and benefit of pruritus measurement in dermatological routine care
• European Prurigo Project (EPP) of the EADV Task Force Pruritus

View on source registry